Search results
Results From The WOW.Com Content Network
[18] [19] Studies conducted using psilocybin in a psychotherapeutic setting reveal that psychedelic drugs may assist with treating depression, alcohol addiction, and nicotine addiction. [11] [20] Although further research is needed, existing results suggest that psychedelics could be effective treatments for certain forms of psychopathology.
[12] [15] The United States Food and Drug Administration has granted "breakthrough therapy" status, which expedites the potential approval of promising drug therapies, [note 2] to psychedelic therapies using psilocybin (for treatment-resistant depression and major depressive disorder) [6] and MDMA (for post-traumatic stress disorder). [17]
In accordance with this, drugs that affect 5-HT-containing cells or 5-HT receptors are effective treatments for numerous indications, including depression, anxiety, obesity, nausea, and migraine. Because serotonin and the related hormone melatonin are involved in promoting sleep, they counterbalance the wake-promoting action of increased ...
Mescaline has a wide array of suggested medical usage, including treatment of depression, anxiety, PTSD, [35] and alcoholism. [36] However, its status as a Schedule I controlled substance in the Convention on Psychotropic Substances limits availability of the drug to researchers. Because of this, very few studies concerning mescaline's activity ...
Subsequently, amphetamine was used in the treatment of narcolepsy, obesity, hay fever, orthostatic hypotension, epilepsy, Parkinson's disease, alcoholism and migraine. [ 12 ] [ 15 ] The "reinforcing" effects of substituted amphetamines were quickly discovered, and the misuse of substituted amphetamines had been noted as far back as 1936.
Designer drugs are structural or functional analogues of controlled substances that are designed to mimic the pharmacological effects of the parent drug while avoiding detection or classification as illegal.
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
A 2012 meta-analysis of fluoxetine and venlafaxine concluded that statistically and clinically significant treatment effects were observed for each drug relative to placebo irrespective of baseline depression severity; some of the authors however disclosed substantial relationships with pharmaceutical industries. [14]